Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Synapticure Presents Early Evidence at CTAD 2026 Supporting Feasibility of Telehealth-Exclusive Specialist Care for Amyloid-Targeted Therapy in Early Alzheimer's Disease

      Synapticure

      News provided by

      Synapticure

      Nov 16, 2026, 09:00 ET

      Share this article

      Share this article


      Analysis of fully remote program included 28 patients across 10 states, treated with lecanemab or donanemab.

      BOSTON, Nov. 16, 2026 /PRNewswire/ -- Synapticure, a national, virtual specialty practice for neurodegenerative disease, today announced data showing that amyloid-targeted therapy (ATT) for early symptomatic Alzheimer's disease can be evaluated, prescribed, and monitored through a fully remote telehealth model. Synapticure will present the findings as Poster P440 on Thursday, November 19, at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston.

      The retrospective study reviewed patients who received lecanemab (Leqembi®) or donanemab (Kisunla®) through Synapticure from July 2025 through October 13, 2026. Neurologists in the Synapticure practice handled evaluation, treatment decisions, and safety monitoring by video. Patients had lab work, amyloid confirmation, MRI, and infusions at facilities near their homes, visits that were coordinated by Synapticure staff.

      The access problem. Lecanemab and donanemab require more than a prescription. Patients need specialized diagnostic evaluation and biomarker confirmation. They need serial MRI monitoring and infusion capacity. They also need a clinician experienced in recognizing and managing amyloid-related imaging abnormalities (ARIA). Specialist expertise is concentrated in urban academic centers. MRI and infusion capacity, by contrast, is more widely distributed. For many patients, the barrier to treatment is access to a specialist, not MRIs and infusion capacity. The feasibility of a remote-only ATT program had not been established in published literature/data.

      The model. Fellowship-trained cognitive neurologists practicing through Synapticure's telehealth platform conducted all specialist care by video, including remote cognitive testing. Each patient had a dedicated Synapticure care coordinator, who did several things by video:

      • Found and vetted local imaging and infusion sites.
      • Identified a nearby hospital most able to manage symptomatic ARIA if inpatient care was needed.
      • Obtained prior authorization.
      • Kept in touch with patients and families between visits.

      Before each label-required monitoring point, the Synapticure care coordinator completed a structured ARIA symptom checklist. The patient then had a local MRI, which was uploaded to a cloud-based imaging system. The treating neurologist reviewed it before the next infusion.

      Key findings (data cutoff October 13, 2026):

      • Reach and scale: 28 patients were treated, 16 with lecanemab and 12 with donanemab. They lived in 10 states spanning all four U.S. Census regions. Three remote neurologists prescribed. Patients received 183 infusions, about 119 patient-months of exposure.
      • Speed to treatment: For patients who started treatment within the program, the median time from prescription to first infusion was 35 days (IQR 27–59). Longer waits reflected insurance difficulties or patient choice.
      • Monitoring held up: All 45 label-required safety MRIs (100%) were completed before the corresponding infusion, a median of 9 days beforehand.
      • Safety: ARIA-E occurred in 2 patients (7%). No macrohemorrhages and no deaths occurred. One patient (4%) discontinued treatment due to ARIA.
      • Completed courses: At the time of data cutoff, three patients had completed a 12-18 month donanemab course with a negative follow-up amyloid PET scan, indicating completion of treatment per the medication's FDA-approved prescribing information.

      What this means. The poster concludes that patients in 10 states were evaluated, treated, and monitored through a telehealth-exclusive model, that label-required MRI monitoring was maintained, and that no unexpected safety signals were seen. These initial findings suggest ATT delivery may not depend on living near a specialist.

      The authors note that the study is small and retrospective. Larger patient numbers and longer follow-up are needed.

      Continued growth. Synapticure's ATT program has continued to grow meaningfully since the poster's data cutoff.

      "We set out to build a model in which patients can safely receive a complex treatment from specialists entirely through telehealth, one where living near the specialist is not a requirement," said Jeremy J. Pruzin, MD, the study's first author. "In our initial experience, patients in 10 states were treated this way. Every required safety MRI was completed before infusion, and both ARIA cases were caught by the monitoring the program was built around."

      "Most of what ATT requires, the imaging and the infusion chairs, already exists in communities across the country. What's scarce is the specialist oversight," said Oleg Yerstein, MD, the study's corresponding author. "This study suggests that specialist care can be delivered remotely, with a remote care coordinator helping the patient navigate local services like infusions and MRIs. It's working with a small cohort, and we're continuing to follow these patients as the program grows."

      "Families affected by Alzheimer's shouldn't have to choose between treatment and a long drive or a months-long wait for a specialist," said Sandra Abrevaya, Chief Executive Officer of Synapticure. "These data are an early sign that a virtual-first model can expand access to new therapies. Indeed, our ATT program has already grown since this analysis, and we anticipate very steep growth ahead as tele-neurology goes truly mainstream."

      Presentation details

      • Title: Fully Remote Telehealth Evaluation and Delivery of Amyloid-Targeted Therapy in Early Symptomatic Alzheimer's Disease: Feasibility and Initial Experience
      • Poster: P440
      • Session: CTAD 2026, Boston, MA, Thursday, November 19, 2026, 7:15 a.m.–5:00 p.m. ET
      • Authors: Jeremy J. Pruzin, MD; Mayra Reyna, NRCMA; Mercedes Guevara, NRCMA; Meagan Gates, LCSW; Sonia Bajwa, MD; Abigail O'Connell, MS, NP; Benjamin Williams, MD; Erin Leahy, MD; Eric Anderson, MD, PhD; Melissa M. Yu, MD; Oleg Y. Yerstein, MD

      About Synapticure

      Synapticure is a national, virtual specialty practice for people living with neurodegenerative and rare neurological diseases. Those diseases include Alzheimer's disease and other dementias, ALS, frontotemporal dementia, Parkinson's disease, Huntington's disease, ataxias, myasthenia gravis, and progressive supranuclear palsy. Synapticure pairs specialist neurologists with dedicated care coordinators to deliver expert care to patients wherever they live. Synapticure also partners with pharmaceutical and biotech companies on clinical research and real-world evidence. Clinical services are provided by neurologists of CareND, an affiliated group of medical practices. Learn more at www.synapticure.com.

      Media contact
      Whitney Gosden
      Head of Marketing, Synapticure
      [email protected] 

      SOURCE Synapticure

      Modal title

      Also from this source

      Synapticure Launches Virtual Myasthenia Gravis Care Program, Expanding Access to Specialized Neuromuscular Care

      Synapticure Launches Virtual Myasthenia Gravis Care Program, Expanding Access to Specialized Neuromuscular Care

      Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative and...

      Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

      Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide

      Synapticure, a leading virtual care company dedicated to improving access and outcomes for patients and caregivers living with neurodegenerative...

      More Releases From This Source

      Explore

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Health Care & Hospitals

      Health Care & Hospitals

      Surveys, Polls and Research

      Surveys, Polls and Research

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.